|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global Blood Plasma Market Report: 2011 Edition
Price: $800.00 (€626.38) ($960.00 (€751.65) Including VAT at 20%)
|
| Publication Date: Feb-2012
Format: PDF Email
Pages: 55
Publisher: Koncept Analytics
Recent scientific studies are leading to the discovery of new proteins in the blood plasma and their uses to treat hitherto unresolved medical conditions. The market for blood plasma products has shown continuous growth in the past years growing at a CAGR of around 10% during 2001-10 and is projected to expand steadily in the years to come.
The North American region is a major revenue generator in the global blood plasma industry, accounting for approximately 40% share of the worldwide market, followed by European Union, and other regions. The use of blood plasma products in developed countries is well established; however, their demand in emerging countries, such as China and India is persistently on the rise.
With scientific, technological advances in medical research in developed and developing countries, there is now much room for increased usage of IVIG. New indications are being explored whereby various blood plasma products are being put to new uses for treatment of old and new diseases. Further, the entry of new recombinant products, which compete with existing blood plasma products, have started a price competition creating a downward pressure on prices. The deficiency of A1PI is still an undiagnosed and untreated disease in North America which provides significant scope and potential for the increased use of blood plasma products in the treatment of the affected people.
Besides this, bleeding disorders and related diseases are growing requiring increased usage of blood plasma products. Ageing population is on the constant rise worldwide and the aged people are prone to develop diseases requiring more demand of blood derivatives. Furthermore, the economic growth is also responsible for higher utilization of blood plasma derivatives. Also, new proteins are being discovered in blood plasma, which are being put to new uses for treatment of various diseases.
Despite, several factors suggesting future growth of the market, the high prices of blood plasma products continues to be a significant challenge. Furthermore, even in the wake of improving economies and rising GDP's, income disparities keep the use of plasma derived products beyond the reach of numerous patients.
The leading players of the blood plasma market include: Baxter, Grifols, CSL, and Octapharma, among others, competing mainly on the basis of product pricing and performance, supply of the products, and continuous offering of new and innovative plasma derivatives. Moreover, the existence of several players operating at a domestic level, entry of new players, and agreements with government agencies, academic and research institutions make the plasma market landscape intensely competitive.
The report provides an analysis of the global blood plasma market. It also discusses the major trends, growth drivers and potential markets for blood plasma market. The report presents the competitive structure of the industry and profiles major players in the market with a discussion of their key business strategies.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Table of Contents/List of Tables/List of Figures |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
R&D Trends: Sepsis - Improvements in clinical trial design and advances in biomarker research hold the key to a tailored approach to sepsis therapy
Price: $3,800.00 (€2,975.28) ($4,560.00 (€3,570.34) Including VAT at 20%)
|
| Publication Date: 06-Apr-2011
Please click here for more information or to purchase this report at our partner store
Progress in sepsis drug development has been severely hindered by the complex disease pathogenesis and patient heterogeneity. This module reviews pipeline trends, clinical trial design, and future treatment paradigms for sepsis. |
|
|
Epidemiology: Sepsis - The incidence of severe sepsis is on the rise due to the dramatic aging populations across the developed world
Price: $5,700.00 (€4,462.92) ($6,840.00 (€5,355.51) Including VAT at 20%)
|
| Publication Date: 29-Mar-2011
Please click here for more information or to purchase this report at our partner store
Overview of sepsis definition and a review of the epidemiology literature. This report provides in-depth analysis of patient populations, and 10-year incident case forecast, and key patient segments across the seven major markets. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial & Pipeline Insight: Antithrombotics – New, switch and repeat – the last battle for antithrombotic blockbusters?
Price: $11,400.00 (€8,925.85) ($13,680.00 (€10,711.02) Including VAT at 20%)
|
| Publication Date: 16-Mar-2011
Please click here for more information or to purchase this report at our partner store
Commercial analysis of the anticoagulant and antiplatelet markets in the US, Japan, France, Germany, Italy, Spain, and the UK. Volume and revenue sales forecast to 2019. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Antidyslipidemics Market Forecast
Price: $15,200.00 (€11,901.13) ($18,240.00 (€14,281.35) Including VAT at 20%)
|
| Publication Date: 23-Aug-2010
Please click here for more information or to purchase this report at our partner store
Forecast of the antidyslipidemic markets in the US, Japan, France, Germany, Italy, Spain, and the UK. Volume and revenue sales forecast to 2019. |
|
|
Stakeholder Opinions: Hemophilia - The harsh reality of commercialising a great research opportunity?
Price: $3,800.00 (€2,975.28) ($4,560.00 (€3,570.34) Including VAT at 20%)
|
| Publication Date: 03-Jun-2010
Please click here for more information or to purchase this report at our partner store
The hemophilia patient population is small, but costs of care for this patient group are a major burden for both developed and developing markets, a burden expected to grow as life expectancies rise and more sufferers demand access to therapeutics. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global Blood Plasma Market Report
Price: $800.00 (€626.38) ($960.00 (€751.65) Including VAT at 20%)
|
| Publication Date: 01-Mar-2010
Format: PDF Email
Pages: 40
Publisher: Koncept Analytics
The global blood plasma products market has undergone drastic changes from the early days when plasma products were considered unsafe and a threat which can result in spreading of diseases like HIV to a product which now helps in saving lives & treating bleeding disorders and helps people to lead a normal life. The global plasma products market has more than doubled over the period 2000-08 as a result of increase in demand and prices of plasma products. The worldwide plasma supply has increased but not at the same pace as the demand for the plasma products. The global plasma products market has been segmented on the basis of plasma proteins like immunoglobulin, albumin, clotting factors and other proteins. The IVIG or Immunoglobulin market is the largest segment of the plasma products market having more than fifty percent share of the market. The IVIG and Albumin segment has been real drivers of the global plasma products market as they witnessed double-digit growth rate over the last few years. The US is the largest market for plasma products consumption as well as in terms of supply of human plasma, as more than fifty percent of global plasma supply comes from the US. The US regulation which allows companies to pay the donor of plasma has significantly contributed towards the high supply of plasma from the US. Among the emerging markets, China is the most potential target market for plasma products. The market has grown significantly over the last few years. The changes in the Chinese plasma product market have significantly contributed towards the global mismatch of demand and supply of plasma and plasma products. Despite, challenges like stringent regulations, ensuring adequate supply of human plasma, the global plasma products market is all set to witness high growth in the coming years as a result of growing world population, increasing bleeding disorder patients, rising US heath expenditure and increasing per capita global GDP. The current report covers the overview, market size and segmentation of the global blood plasma market. The various drivers, opportunities and the challenges faced by the market are also discussed in detail. The competitive aspect of the market is highlighted and the key players are profiled with their strategies for this market. By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Table of Contents/List of Tables/List of Figures |
|
|
Be alerted by email of new featured reports
Browse upcoming events or submit your own